Skip to main content

Table 1 Patient characteristics

From: Conversion back to bevacizumab or ranibizumab for recurrent neovascular activity with aflibercept in age-related macular degeneration: a case series

Total eyes, N 21
Total patients, N 19
Female, N (%) 11 (58)
Age, years (range) 79 (67–95)
Number of bevacizumab and ranibizumab injections prior to aflibercept, mean (range) 20.71 (3–49)
Aflibercept injections, mean (range) 7.19 (3–14)
Injection interval in weeks while on aflibercept, mean ± SD 6.08 ± 1.12
Injection interval in weeks between last aflibercept injection and first bevacizumab or ranibizumab injection, mean ± SD 5.97 ± 3.24
  1. Description of patients with chronic neovascular age-related macular degeneration transitioned from bevacizumab or ranibizumab to aflibercept and then back to bevacizumab or ranibizumab